Legend Biotech (LEGN) Receivables - Net (2019 - 2025)

Legend Biotech has reported Receivables - Net for 7 years, with the latest figure at $13.1 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Net rose 104.69% year-over-year to $13.1 million; the trailing twelve-month figure through Dec 2025 stood at $13.1 million (up 104.69% YoY), and the FY2025 full-year result was $13.1 million, up 108.37% from the prior year.
• Receivables - Net for Q4 2025 stood at $13.1 million, up from $1.2 million in the prior quarter.
• The five-year high for Receivables - Net was $100.0 million in Q4 2023, with the low at $1967.0 in Q1 2021.
• Historically, Receivables - Net has averaged $16.6 million across 5 years, with a median of $4.9 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net jumped 2564770.36% — and 2023, when it sank 99.89%.
• Legend Biotech's Receivables - Net stood at $50.4 million in 2021, then slumped by 99.82% to $90000.0 in 2022, then surged by 111056.67% to $100.0 million in 2023, then plunged by 93.6% to $6.4 million in 2024, then soared by 104.69% to $13.1 million in 2025.
• The last three Receivables - Net figures came in at $13.1 million (Q4 2025), $1.2 million (Q3 2025), and $27.6 million (Q2 2025), per Business Quant data.